Stock events for STERIS Plc (Ireland) (STE)
In the past six months, STERIS Plc's stock experienced several notable events. For fiscal year 2025, STERIS reported a 6% revenue increase, reaching $5.5 billion, with diluted EPS rising to $6.16. In Q1 2026, the company reported EPS of $2.34, beating estimates, and revenue grew 9% to $1.39 billion, surpassing forecasts. The quarterly dividend was increased by 10% to $0.63. The stock price increased by 14.06% over the past six months, reaching a 52-week high of $253.03. As of September 30, 2025, the share price was $247.41, an increase of 2.01% from September 30, 2024. STERIS stock has received a consensus 'buy' rating from analysts.
Demand Seasonality affecting STERIS Plc (Ireland)’s stock price
The provided search results do not contain specific information regarding the demand seasonality for STERIS Plc's products and services. However, the company's business model, which includes recurring revenue from service contracts, consumable products, and ongoing maintenance agreements, suggests a relatively stable demand. The consistent healthcare spending and increasing demand for sterilization and disinfection products also contribute to a stable outlook.
Overview of STERIS Plc (Ireland)’s business
STERIS Plc is a global medical equipment company specializing in infection prevention and other procedural products and services, operating primarily within the healthcare, life sciences, and medical device industries. The company aims to help customers create a healthier and safer world by providing innovative healthcare and life science products and services globally. Its offerings include capital equipment like surgical tables and sterilizers, consumable products such as endoscopy accessories and detergents, services like equipment maintenance and laboratory testing, and applied sterilization technologies (AST) providing contract sterilization and testing services.
STE’s Geographic footprint
STERIS Plc has a significant global presence with operations in North America and Latin America. The company operates directly in 18 countries and works with distribution partners in over 100 countries. While operationally headquartered in Mentor, Ohio, U.S., STERIS Plc is legally registered in Dublin, Ireland, for tax purposes since 2018.
STE Corporate Image Assessment
STERIS maintains a strong reputation for quality and innovation, supported by its position as a global leader in infection prevention, sterilization, and surgical technologies. The company actively invests in research and development, with 37 new product launches and 672 active patents reported in 2023. Recent events contributing to its reputation include new product introductions, additional disinfectant and virucidal activity claims for its CIP 200 Acid-Based Cleaner and Disinfectant, industry recognition such as the 2022 Pharma Innovation Awards, and expanded services through Extractables and Leachables testing and the acquisition of Cantel Medical. No significant negative events impacting STERIS Plc's brand reputation in the past year were found.
Ownership
STERIS Plc features a mixed ownership structure, with a significant portion held by institutional investors. Institutional investors own approximately 93.22% to 93.65% of STERIS plc stock, with largest shareholders including Vanguard Group Inc., BlackRock Inc., Massachusetts Financial Services Co /ma/, State Street Corp, Morgan Stanley, Generation Investment Management Llp, and Geode Capital Management, Llc. Individual investors hold around 4.88% to 5.85% of shares, while insiders own approximately 0.93% to 0.94% of the shares.
Ask Our Expert AI Analyst
Price Chart
$237.81